10.199% filed a letter requesting the company to hold extraordinary shareholders? meeting to consider the matters of (1) rights offering of newly issued shares and share warrants and (2) change of the

in the environmental and social areas, which include respect for human rights and good corporate governance. For example, climate change risk, biohygienic and safety risk, disputes with the community

a link thereto in order for investors to be able to access such information conveniently. Such information must be kept for at least five years without change thereafter. In addition, the Company is

SUMMARY EXECUTIVE SUMMARY 2 2017 2018 % change Q3’2018 Q4’2018 % change million Baht million Baht y-on-y million Baht million Baht q-on-q Sales and service income 31,482 36,585 16.2% 9,691 9,933 2.5% EBITDA

EXECUTIVE SUMMARY 2 Q1’2017 Q1’2018 % change Q4’2017 Q1’2018 % change million Baht million Baht y-on-y million Baht million Baht q-on-q Sales and service income 7,651 8,156 6.6% 7,762 8,156 5.1% EBITDA 2,133

63.1% of NNP. ABBREVIATION & OUR PROJECTSFINANCIAL PERFORMANCE FINANCIAL POSITION PROGRESS OF PROJECTS UNDER CONSTRUCTION EXECUTIVE SUMMARY EXECUTIVE SUMMARY 2 6M’2017 6M’2018 % change Q1’2018 Q2’2018

EXECUTIVE SUMMARY EXECUTIVE SUMMARY 2 9M’18 9M’19 change Q3’18 Q2’19 Q3’19 change change Btmn Btmn y-on-y Btmn Btmn Btmn y-on-y q-on-q Sales and service income 26,652 32,874 23.3% 9,691 10,866 11,751 21.3

EXECUTIVE SUMMARY EXECUTIVE SUMMARY 2 6M’18 6M’19 change Q2’18 Q1’19 Q2’19 change change Btmn Btmn y-on-y Btmn Btmn Btmn y-on-y q-on-q Sales and service income 16,961 21,123 24.5% 8,805 10,257 10,866 23.4

change in net working capital and cash tax, before maintenance capex Indorama Ventures 2nd Quarter 2019 MD&A 3 Summary 2Q19 results IVL’s performance for the first half and ongoing progress give us the

granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change